论文部分内容阅读
目的分析结肠癌术中腹腔热灌注化疗的安全性和治疗价值。方法选取2010年6月至2015年6月50例诊断结肠癌患者随机分为术中腹腔热灌注化疗组(治疗组,26例)和单纯手术组(对照组,24例)。两组术后均以FOLFOX4方案全身化疗6个疗程。观察并比较灌注化疗的安全性和术后1、2、3年生存率情况。结果两组术后并发症和毒副反应无明显差异(P均>0.05)。随访3年,两组1、2年生存率比较差异无统计学意义(P均>0.05),3年生存率比较,治疗组明显优于对照组(P<0.05)。结论结肠癌术中腹腔热灌注化疗安全性好,可提高患者生存率。
Objective To analyze the safety and therapeutic value of intraperitoneal hyperthermic perfusion chemotherapy in colon cancer. Methods Fifty patients diagnosed with colon cancer from June 2010 to June 2015 were randomly divided into intraperitoneal hyperthermic perfusion chemotherapy group (treatment group, 26 cases) and simple operation group (control group, 24 cases). Two groups of patients were treated with FOLFOX4 systemic chemotherapy six courses. Observe and compare the safety of perfusion chemotherapy and postoperative 1, 2, 3-year survival rate. Results There were no significant differences in postoperative complications and adverse reactions between the two groups (all P> 0.05). After 3 years of follow-up, there was no significant difference in the 1-year and 2-year survival rates between the two groups (all P> 0.05). The 3-year survival rate was significantly better in the treatment group than in the control group (P <0.05). Conclusion Intraperitoneal hot perfusion chemotherapy in colon cancer is safe and can improve the survival rate of patients.